Clinical Trial: a4b7 Integrin in Eosinophilic Esophagitis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis

Brief Summary: The overall objective of this preclinical study is to further the investigators mechanistic understanding of the role that the α4β7 and mucosal addressin cell adhesion molecule (MAdCAM-1) pathway plays in mediating eosinophil recruitment in EoE. To accomplish this, the investigators aim to (1) determine the baseline and dynamic patterns of α4β7 integrin expression on circulating and tissue eosinophils in EoE and in the setting of non-EoE esophageal eosinophilia (e.g., reflux esophagitis) and (2) determine the complete profile of eosinophil integrin molecules that may play a role in active EoE.

Detailed Summary:
Sponsor: Massachusetts General Hospital

Current Primary Outcome: Percentage of eosinophils expressing a4b7 integrin [ Time Frame: 8 weeks ]

Eosinophil expression levels of a4b7 integrin will be assessed on peripheral and esophageal eosinophils during active EoE and after treatment-induced remission.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Massachusetts General Hospital

Dates:
Date Received: September 8, 2015
Date Started: March 2016
Date Completion: March 2018
Last Updated: March 21, 2017
Last Verified: March 2017